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Abstract The hypertriglyceridemia of diabetes can be
classified into mild to moderate (triglycerides between
150–499 mg/dL) and severe hypertriglyceridemia (trigly-
cerides ≥500 mg/dL). As in any other individuals with
hypertriglyceridemia, secondary causes need to be excluded.
The management of severe hypertriglyceridemia (chylomi-
cronemia syndrome) includes aggressive reduction of trigly-
cerides with intravenous insulin, fibrates, omega-3 fatty
acids, and/or niacin therapy to avert the risk of pancreatitis.
In patients with mild to moderate hypertriglyceridemia, the
treatment of choice is statin therapy to achieve the low-
density lipoprotein (LDL) and non-high-density lipoprotein
(HDL) target goals. The evidence base would favor niacin
therapy in combination with statin therapy to achieve the
goals pertaining to LDL cholesterol and non-HDL choles-
terol. The data about the combination of fibrate therapy with
statin therapy are disappointing.
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Introduction
The major cause of morbidity and mortality in type 2 diabetes
is cardiovascular disease (CVD). Regarding the lipid profile
in patients with type 2 diabetes mellitus (T2DM), the usual
abnormalities include hypertriglyceridemia (HTG) and low
levels of high-density lipoprotein-cholesterol (HDL-C).
However, in the UKPDS [1], low-density lipoprotein-
cholesterol (LDL-C) levels were significantly increased in
women, but not in men. Thus, the major abnormalities with
the respect to the dyslipidemia in T2DM include increased
number of triglyceride-rich particles, increased postprandial
concentrations of triglyceride-rich particles, increased num-
ber of LDL particles, small dense LDL particles, decreased
HDL particle numbers, and several changes in particle
composition of HDL [2]. Also, we have shown that
remnant-like particle cholesterol levels are elevated in
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diabetic patients [3]. When risk factors are ranked in patients
with T2DM for CVD, LDL-C and HDL-C are most
important [4]. Following diet and exercise, the cornerstone
of treatment for the dyslipidemia of diabetic patients is 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
(statin) therapy. In the CTT Collaborators study [5••], a
meta-analysis of 14 randomized statin trials, it was shown
that each millimole reduction in LDL-C (38.6 mg/dL of
LDL-C) was associated with a 21% reduction in major
vascular events and a 21% reduction in stroke. The benefits
of statin therapy were evident in diabetic patients both with
and without a prior history of vascular disease [5••].
The major focus of this review is the management of
HTG in diabetes. Table 1 demonstrates a practical classi-
fication of HTG in diabetes. HTG will be discussed under
two broad categories: “mild to moderate,” in which the
triglycerides are between 150 to 499 mg/dL, and “severe
HTG,” when the triglyceride levels are ≥500 mg/dL. As in
any other patient with HTG, it is important to take into
account the other causes, which include obesity, alcohol-
ism, renal disease, drugs (eg, steroids, β blockers, retinoids,
oral estrogens, tamoxifen, protease inhibitors, and bile acid
sequestrants), lipodystrophy, and pregnancy (Table 1).
Management of Severe HTG
With respect to severe HTG, also referred to as chylomi-
cronemia syndrome, triglyceride levels are generally greater
than 1,000 mg/dL and usually greater than 2,000 mg/dL. In
children this can result from a deficiency of lipoprotein
lipase (LPL) or its cofactor, apolipoprotein (apo) C-II.
However, the focus of this review is in the more common
type V hyperlipidemia seen in adults. These patients have
both elevated levels of very low density lipoproteins
(VLDLs) and chylomicrons. The major risk for these
patients is pancreatitis. Other clinical features in patients
with chylomicronemia syndrome include eruptive xan-
thoma, hepatosplenomegaly, lipemia retinalis, abdominal
pain with or without pancreatitis, peripheral neuropathy,
dyspnea, memory loss, and dementia. There is an excellent
review on this topic by Chait and Brunzell [6]. The
management of severe HTG is important to achieve a
triglyceride level less than 500 mg/dL to prevent pancrea-
titis. Thus, in these patients the fat intake should be reduced
to less than 10–15% of total calories.
In a patient who is admitted to a hospital, it would be
reasonable to start them on intravenous insulin and allow
no calories by mouth if there is poor diabetes control,
newly diagnosed diabetes, or they present with pancreatitis.
In addition, they can be started on fibrate therapy and also
omega-3 fatty acids. After the patient is discharged and
diabetes control is reasonable with hemoglobin A1c as close
to 7%, one can institute niacin therapy in addition, to target
triglyceride levels less than 500 mg/dL. In clinical practice,
triple therapy with a fibrate, niacin, and omega-3 fatty acids
is sometimes required to target the HTG. The dose of
omega-3 fatty acid that has been found to be efficacious
ranges from 4 to 10 g/d. In this regard, the prescription
Lovaza (Pronova BioPharma, Lysaker, Norway) of omega-
3 ethyl ester concentrate, a rich source of omega-3 fatty
acid (840 mg/1-g capsules), can prove very efficacious in
lowering triglycerides [7].
There is some debate within the literature regarding the
role of continuous intravenous heparin in the treatment of
severe HTG. It has been established that unfractionated
heparin infusion can lead to an increase in the release of
LPL [8]. This results in a temporary increase in lipolysis
and, therefore, lower triglyceride levels. However, the
circulating heparin-apoenzyme complex undergoes hepatic
metabolism and degradation, which ultimately leads to a
significant decrease in lipolysis activity [9, 10]. If the rate
of hepatic metabolism/degradation of LPL exceeds the
release of LPL from peripheral tissues, the net result would
be worsening of HTG [9, 10]. Thus, we do not recommend
heparin therapy.
Hospitalized patients may also benefit greatly from
inpatient education to emphasize the importance of main-
taining an improved lipid profile and potential dangers
associated with poor lipid control. Nutritionist and/or endo-
crine consultation to discuss dietary, lifestyle, and exercise
modifications would be appropriate for such individuals.
Management of Mild to Moderate HTG
Sarwar et al. [11] reported in a recent meta-analysis that
triglyceride levels are an independent cardiovascular risk
factor even when adjusted for HDL-C. For mild to
moderate HTG, consideration should be given to familial
dyslipidemias that include familial combined hyperlipid-
emia, familial HTG, and familial dysbetalipoproteinemia
Table 1 Diabetic hypertriglyceridemia
Mild to moderate: 150–499 mg/dL





Drugs (eg, steroids, β blockers, retinoids, oral estrogens,
tamoxifen, protease inhibitors, bile acid sequestrants)
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(type III dyslipidemia). Familiar HTG is an autosomal-
dominant disorder with elevated levels of VLDL-cholesterol
(VLDL-C) mainly due to large VLDL particles [12, 13••].
These patients generally have normal levels of LDL-C and
apo B levels and can have low levels of HDL-C [12, 13••].
They do not appear to have an increased risk for CVD
unless they also have enough features to define them as
having the metabolic syndrome. Familial combined hyper-
lipidemia is also an autosomal-dominant disorder with an
overproduction of apo B-100 particles [13••]. In this
disorder, there is a family history of premature heart
disease; and family members can have elevated levels of
cholesterol, triglycerides, or combined hyperlipidemia.
These patients are at increased risk for premature coronary
artery disease (CAD) and have elevated apo B levels [13••].
Invariably these patients have a preponderance of small
dense LDL particles. The third familial disorder that can
result in mild to moderate HTG is type III dyslipidemia or
dysbetalipoproteinemia. These patients usually are homo-
zygous for apo E2; its frequency in the population is
approximately 1% and can be easily determined by
genotyping for apoprotein E. However, to manifest type
III hyperlipoproteinemia, a second hit is required; this
usually is a secondary factor such as diabetes, obesity,
hypothyroidism, or renal disease. They classically present
with cholesterol and triglyceride levels in the same order of
magnitude between 200 to 600 mg/dL. Clinically, these
patients present with tuberoeruptive xanthomas and xan-
thomas in palm creases (xanthoma palmaris striata), and
can manifest features of CAD and peripheral arterial
disease. They have elevated levels of VLDL-C and
intermediate-density lipoprotein cholesterol and low levels
of HDL-C and LDL-C by β quantification. On electropho-
resis, they have a broad β band spanning the pre-β/β area.
The diagnostic test for type III hyperlipoproteinemia is
ultracentrifugation and reporting the VLDL-C/total trigly-
cerides ratio. In patients with type III hyperlipoproteinemia,
a ratio of greater than 0.3 is diagnostic and usually means
that there is β-VLDL present. Table 2 depicts laboratory
tests that can be useful in the workup of patients with HTG.
With respect to the management of mild to moderate
HTG, therapeutic lifestyle change is a primary treatment,
with a focus on reduction of saturated fat, cholesterol, trans
fat, refined carbohydrates, and encouragement of a high-
fiber diet with at least 30–40 g/d. Cigarette use is another
modifiable risk factor that can be part of life-style changes.
Smoking cessation results in an improved lipid profile
despite the weight gain that often occurs after one stops
smoking [13••]. In addition, statin therapy will be the
treatment of choice to achieve levels of LDL-C less than
100 mg/dL and non-HDL-C less than 130 mg/dL in
patients with diabetes without CVD [14]. In a diabetic
patient with CVD, the LDL-C goal is less than 70 mg/dL
and the non-HDL-C goal is less than 100 mg/dL. The non-
HDL-C goal should also be a secondary target, especially if
the triglyceride levels are greater than 150 mg/dL [14]. In
achieving these goals, in addition to statin therapy, one has
to consider combination therapy with niacin, fibrates, or
omega-3 fatty acids.
Regarding therapeutic lifestyle change and HTG, body
weight control is critical, regular physical activity should be
encouraged, alcohol intake should be restricted, and
avoidance of high-carbohydrate diets (especially with
refined carbohydrates) should be encouraged. The evidence
base for niacin therapy in diabetic patients on statins is
scant. However, niacin therapy has been known to reduce
LDL-C, non-HDL-C, and triglycerides, and increase HDL-
C. In the CDP, niacin therapy resulted in reduction of
cardiovascular events (CVEs) and mortality in patients with
CAD [15]. Side effects of niacin therapy include flushing,
abnormal liver function tests, hyperglycemia, and hyperuri-
cemia. Generally, niacin therapy should be combined with
statin therapy in patients with mild to moderate HTG, if the
hemoglobin A1c is around 7% (ie, good diabetes control).
In the HATS study, there was a clear benefit of the
combination of simvastatin/niacin therapy versus placebo
on both coronary angiographic progression and CVEs.
However, only 16% of the 160 patients with coronary heart
disease (CHD) were diabetic [16]. In the ARBITER 3
study, patients were followed up for 24 months and carotid
intima-media thickness (IMT) regression was evident with
niacin therapy. The subcohort with diabetes or the meta-
bolic syndrome included 62 patients [17]. In the ARBITER
6-HALTS study, which comprised 208 patients with CHD
or CHD risk equivalent, all of whom were on statin therapy
with LDL levels less than 100 mg/dL and HDL-C levels
below 50 and 55 mg/dL in men and women, respectively,
40% of the patients on ezetimibe and 32% on niacin were
diabetic [18]. Niacin therapy resulted in significant reduc-
tion in mean and maximum carotid IMT over 14 months
and decrease in major CVEs. The effect of niacin therapy
on mean carotid IMT was consistent across prespecified
subgroups including presence and absence of diabetes [18].
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Studies that are in progress that include diabetic patients are
the AIM HIGH study with a comparison of niacin/
simvastatin versus simvastatin therapy on CVD, and also
the HPS2-THRIVE study in which niacin combined with
laropiprant (D2 antagonist) plus statin therapy is being
examined. Because both of these studies include diabetic
patients, they will better inform us about niacin therapy in
addition to statins in patients with mild to moderate
hypertriglyceredemia to reduce the residual risk that is
manifest even in statin-treated diabetics. Although the
sample sizes of diabetic patients are small in the studies
summarized above, the collective results are promising.
The best data about peroxisome proliferator-activated
receptor-α agonist fibrate therapy (fibrate therapy in
patients with diabetes) is the VA-HIT study. In this study,
they showed that in the 627 diabetic patients there was 24%
reduction in the expanded end point of death from CHD,
nonfatal myocardial infarction (MI), and confirmed stroke
(P=0.05) in the diabetic group who received gemfibrozil
compared with placebo [19]. In a subsequent report, in
which the diagnosis of diabetes was modified to include the
new criteria of fasting plasma glucose ≥ 126 mg/dL, the
total cohort of diabetic patients was increased to 769 and
there was a 32% risk reduction of the composite end point
of CHD death, stroke, or MI (P=0.004) [20]. This decrease
was largely due to a reduction in CHD death. In the DAIS,
418 T2DM patients were randomized to fenofibrate
(200 mg/d) or placebo for 3 years [21]. There were
significant reductions in LDL-C, triglycerides, and
increases in HDL-C. In the group that received fenofibrate,
there was significantly less coronary angiographic progres-
sion in minimum lumen diameter and percent diameter
stenosis. There was no significant effect on average of
mean segment diameter. Also, there was a decrease in the
incidence of microalbuminuria. In the FIELD study, 9725
T2DM patients not on statin therapy, 2131 with previous
CVD with total cholesterol between 116 to 251 mg/dL, and
triglyceride levels between 88.6 to 443 mg/dL were studied.
The primary outcome in the study was CHD death and
nonfatal MI. During the trial 17% of the placebo and 8% of
the fenofibrate group started other lipid therapy, which was
mainly statins. At study end, there was a 22% reduction in
triglycerides, 6% decrease in LDL-C, and 1% increase in
HDL-C [22]. There was a nonsignificant 11% reduction
in the primary end point (P=0.16), 24% reduction in
nonfatal MI (P=0.01), nonsignificant increase in CHD
mortality of 19% (P=0.22), and total CVE (comprising
CVD death, MI, stroke, and revascularization) was reduced
by 11% (P=0.035). Other significant effects in the study
included reduction in albuminuria and retinopathy needing
laser therapy. Also, there was significant increased risk of
pancreatitis and pulmonary embolism, and increase in both
homocysteine and creatinine levels.
With regard to the fibrate therapy, side effects include
gastrointestinal symptoms. Although there is an increased
excretion of biliary cholesterol, there does not seem to be
any increased risk of gallstones with fenofibrate therapy.
Both fenofibrate and gemfibrozil displace warfarin from
protein binding, so the warfarin dose has to be titrated in
these patients to achieve their goal International Normalized
Ratio. There also appeared to be an increase in both
creatinine and homocysteine levels with fenofibrate thera-
py. Furthermore, the combination of statin and fibrate,
especially gemfibrozil, in patients with renal failure,
cholestasis, hypothyroidism, and aging increases the risk
of rhabdomyolysis. It appears that gemfibrozil interferes
with statin glucuronidation.
The final study is the ACCORD study (lipid arm), which
was published recently [23••]. In this study, 5518 patients
on fenofibrate and simvastatin were compared to simvas-
tatin therapy and they were followed up for a mean duration
of 4.3 years. There was no significant benefit on the
primary end point, which was a composite of nonfatal MI,
nonfatal stroke, and CVD death or any of the prespecified
secondary end points [23••]. Also, in the prespecified
subgroup analyses, there was a benefit for men and possible
harm for women. A trend to benefit was evident (P=0.057)
in patients with both high triglyceride levels (≥204 mg/dL)
and low levels of HDL-C (<34 mg/dL). As in the FIELD
and DAIS studies, there was a lower incidence of both
microalbuminuria and macroalbuminuria in the fenobibrate
group despite a significant increase in creatinine and
decrease in glomerular filtration rate. Of interest, the group
receiving a combination of fenofibrate and simvastatin did
not have a statistically significant increase in myositis or
rhabdomyolysis in the ACCORD trial [23••]. The inves-
tigators stated in their conclusion that their results do not
support the routine use of fenofibrate in combination with
simvastatin to reduce CVEs in the majority of patients with
diabetes.
Conclusions
For diabetic dyslipidemia, statins are the drug of choice. In
patients with severe HTG, especially triglyceride levels
greater than 1,000 mg/dL, fibrate therapy and/or niacin and
fish oil should be used to lower triglyceride levels to less
than 500 mg/dL and to avert the risk of pancreatitis.
Intravenous insulin may be considered as another thera-
peutic option for hospitalized individuals. In patients with
mild to moderate HTG, consideration should be given to
adding niacin to get both the LDL-C and non-HDL-C levels
to goal, especially if the hemoglobin A1c is around 7%. The
combination of fibrate therapy to statin as evidenced by the
ACCORD study has been disappointing. The greatest
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benefit for this combination therapy appears to be in
patients who have low HDL-C and elevated triglyceride
levels, as shown by subgroup analysis and post hoc
analyses of the FIELD study [24].
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